Yahoo India Web Search

Sign In

Search results

    • Image courtesy of researchgate.net

      researchgate.net

      • Chronic obstructive pulmonary disease (COPD) treatment strategies call for a tailored approach to patient needs, in which therapies are introduced to relieve symptoms, improve health status and exercise tolerance, and reduce future risk and severity of exacerbations (including prevent disease progression, prevent and treat exacerbations and reduce mortality). 1 Bronchodilator therapy with long-acting muscarinic antagonist (LAMA) and/or long-acting β2-agonist (LABA) is the recommended initial...
      www.ncbi.nlm.nih.gov/pmc/articles/PMC10474219/

      Clinical Concepts for Triple Therapy Use in Patients with ...

  2. People also ask

  3. www.ncbi.nlm.nih.gov › pmc › articlesThe 2023 GOLD Report: Updated Guidelines for Inhaled...

    Jul 20, 2023 · The most recent (2023) GOLD Report has several updates relevant to COPD treatment, including updated definitions of COPD, recent associations of inhaled pharmacological therapy with mortality, expanded discussion related to inhaled drug delivery and adherence to inhaled medication, and updated recommendations for initial and follow-up ...

    • Paul D. Terry, Rajiv Dhand
    • Pulm Ther. 2023 Sep; 9(3): 345-357.
    • 10.1007/s41030-023-00233-z
    • 2023/09

  4. www.gloshospitals.nhs.uk › COPD_Inhalers_2023COPD INHALER PRESCRIBING GUIDELINE

    Consider a trial of triple therapy. Perform CAT test before initiation and.

  5. www.nejm.org › doi › fullTriple Inhaled Therapy at Two Glucocorticoid Doses in ...

    Jun 24, 2020 · Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β 2 -agonist (LABA) for chronic obstructive pulmonary disease (COPD)...

    • Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson, Chen Wang, Dave Singh, Jadwiga A. Wedzicha, R...
    • 2020

  6. Videos

    View all

  7. www.ncbi.nlm.nih.gov › pmc › articlesBeyond Dual Bronchodilation – Triple Therapy, When and Why

    Jan 14, 2022 · A recent network meta-analysis aimed to directly compare triple ICS/LABA/LAMA with corresponding either dual LABA/LAMA or ICS/LABA therapies administered as FDC via the same inhaler device has provided important information on the possible positioning of triple therapy FDC in the treatment of COPD. 29 It included ETHOS (Efficacy and Safety of ...

  8. www.bmj.com › content › 363Triple therapy in the management of chronic obstructive ...

    Nov 6, 2018 · Triple therapy was associated with a significantly reduced rate of moderate or severe exacerbations compared with LAMA monotherapy (rate ratio 0.71, 95% confidence interval 0.60 to 0.85), LAMA and LABA (0.78, 0.70 to 0.88), and ICS and LABA (0.77, 0.66 to 0.91).

    • Yayuan Zheng, Jianhong Zhu, Yuyu Liu, Weiguang Lai, Chunyu Lin, Kaifen Qiu, Junyan Wu, Weimin Yao
    • 2018

  9. www.ncbi.nlm.nih.gov › pmc › articlesTriple therapy in COPD: understanding the data - PMC

    Jan 30, 2023 · A foremost question for the clinician is stepping up treatment from a LAMA-LABA inhaler to triple therapy. Three major trials have compared the effectiveness and safety of various single-inhaler triple therapy agents with single-inhaler dual bronchodilators, particularly LAMA-LABA, on major outcomes in patients with COPD [2–4]. The ...

  10. openres.ersjournals.com › content › 5/1/00185-2018Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the ...

    A current hot topic in COPD is that two “fixed triple” combinations of an inhaled corticosteroid (ICS), a long-acting β 2 -agonist (LABA) and a long-acting muscarinic antagonist (LAMA) in a single inhaler have become available for patients with COPD, and a third triple therapy is in advanced development with the first large randomised clinical t...